KLRC1 and neoplasm: [8] discovered that HLA‐E plays a pivotal role in enabling circulating tumor cells to evade host immune surveillance, whereas circulating tumor cells (CTCs) avoid NK cell surveillance and inhibit tumor metastasis through an immune checkpoint molecular pair known as HLA‐E: CD94‐NKG2A.